Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.45 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.36 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.36 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.36 |
| ▸ | IMPDH2 | P12268 | 6/20 | 0.35 |
| ▸ | IMPDH1 | P20839 | 2/20 | 0.35 |
| ▸ | PI4KA | P42356 | 1/20 | 0.34 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.34 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.34 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.34 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.34 |
| ▸ | KRAS | P01116 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3317477 | 1.00 | TAS1R3 (0.45) | TAS1R3TAS1R1KDM4EMEN1KMT2A | |
| SCHEMBL14134583 | 0.92 | TAS1R3 (0.44) | TAS1R3TAS1R1KDM4EMEN1KMT2A | |
| SCHEMBL3317482 | 0.89 | TAS1R3 (0.44) | TAS1R3TAS1R1KDM4EMEN1KMT2A | |
| SCHEMBL3316463 | 0.88 | TAS1R3 (0.55) | TAS1R3TAS1R1KDM4EIMPDH2IMPDH1 | |
| SCHEMBL3316465 | 0.88 | TAS1R3 (0.55) | TAS1R3TAS1R1KDM4EIMPDH2IMPDH1 | |
| SCHEMBL24197045 | 0.84 | TAS1R3 (0.44) | TAS1R3TAS1R1KDM4EMEN1KMT2A | |
| SCHEMBL26347601 | 0.84 | TAS1R3 (0.44) | TAS1R3TAS1R1KDM4EMEN1KMT2A | |
| SCHEMBL15828296 | 0.82 | KDM4E (0.51) | TAS1R3TAS1R1KDM4EMEN1KMT2A | |
| SCHEMBL25404255 | 0.81 | TAS1R3 (0.64) | TAS1R3TAS1R1KDM4EP2RX1P2RX3 | |
| SCHEMBL24181934 | 0.81 | KDM4E (0.48) | TAS1R3TAS1R1KDM4EMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8324179-B2 | Nucleoside analogs for antiviral treatment | GILEAD SCIENCES, INC. (US) | 2012-12-04 | — | — | US | disclosed |
| US-20100104532-A1 | NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES, INC. (US) | 2010-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100104532-A1 | NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT | SLC29A1, NUDT1, EIF2AK2 | TAS1R3 4231/4885TAS1R1 3479/4885KDM4E 3824/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.